Navigation Links
Tethys Bioscience Hits Key Milestones With Series C Funding, Opening of CLIA Laboratory
Date:1/10/2008

Biomarker discovery company builds strong financial and clinical foundation in preparation for release of technology enabling early detection of risk

for diabetes

EMERYVILLE, Calif., Jan. 10 /PRNewswire/ -- Tethys Bioscience today announced that it has reached two significant milestones in its drive to release Tethys Diabetes PreDxTM, a multi-biomarker technology that provides a more complete picture of an individual's future risk of developing diabetes. The company received its latest round of funding (Series C), and also received the licensing of its CLIA Lab by the State of California. Both moves place Tethys Bioscience in a strong position to establish itself as a leader in the emerging field of personalized predictive medicine and to achieve its goal of helping to stem the burgeoning epidemic of chronic, high-burden metabolic disease. Tethys Diabetes PreDxTM will be generally available in the first half of 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO)

The new round of funding is led by Intel Capital, which was created specifically to invest in innovation and has a strong interest in the emerging field of predictive personalized medicine. This latest financing, a process begun with earlier investments from some of the leading venture capital firms, including Kleiner Perkins Caufield & Byers and MDV-Mohr Davidow Ventures, results in a total of $54 million in financing, to date.

"We're very pleased to receive this round of financing from our investors, and believe it supports our vision to dramatically improve the detection and treatment, and ultimately prevention, of chronic diseases," said Mickey Urdea, CEO of Tethys Bioscience. "It gives us the resources to accelerate our work in this critical field, and to introduce a technology that enables a clinically simple blood test that provides an objective means to identify individuals at highest risk for diabetes. Our test will give medical professionals, and their patients, the opportunity to intervene and modify the risk before irreversible damage occurs.

Tethys Bioscience also announced the licensing of its clinical lab by the State of California. This marks a significant step forward for the company, enabling it to make its testing services available for sale and to offer test results obtained in Tethys' own laboratory, where the technology was also developed.

There is a very large market for early detection technology enabling personalized preventive efforts in diabetes and other chronic diseases. It is estimated that up to 7% of the population, or nearly 21 million people, have diabetes, with more than six million of those currently undiagnosed. Further, the number of individuals at risk for diabetes is estimated to be greater than double the number of those with diabetes. Tethys Diabetes PreDxTM involves a simple to administer blood test, which fits easily into current clinical practice and provides clinically important, personalized risk information -- while matching or outperforming traditional clinical risk scores and measures of glucose dysregulation or insulin resistance. About Tethys BioscienceTethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers -- biomarkers -- that provide a practical tool to address the growing global healthcare challenge of chronic metabolic diseases such as diabetes. Tethys Bioscience comes to market with a unique combination: management, research, and commercialization teams with extensive experience in diagnostic innovation, strategic alliances with world-class researchers and partners, and a solid financial foundation to help transform the management of chronic diseases with personalized, preventive solutions that aid every constituency: patients, doctors, and the healthcare system as a whole.


'/>"/>
SOURCE MDV-Mohr Davidow Ventures
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
3. Connecticut Bioscience Achievement Awards Presented at CURE Annual Meeting
4. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
5. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
6. KGI and Smith College Announce Speakers for Women Leadership Forum in Bioscience
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
9. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology: